Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Apr
12
Today In Oncology
Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL
Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo